Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

Cancer

Volumn 110, Issue 6, 2007, Pages 1178-1186

  Piccaluga, Pier Paolo ^a   Paolini, Stefania ^a   Martinelli, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute lymphoid leukemia; BCR ABL1; Dasatinib; Imatinib; Nilotinib; Ph+ ALL; Philadelphia chromosome positive acute lymphoblastic leukemia; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; BCR ABL PROTEIN; BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NILOTINIB; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG BINDING; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEVER; GENE EXPRESSION; GENE MUTATION; HUMAN; MONOTHERAPY; NAUSEA; NEUTROPENIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECURRENCE; SURVIVAL ANALYSIS; THIAZOLES; TREATMENT OUTCOME;

EID: 34548744667     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22881     Document Type: Review

References (37)

1. Sobol RE, Royston I, LeBien TW, et al. Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies. Blood. 1985;65:730-735.
2. Foon KA, Billing RJ, Terasaki PI, Cline MJ. Immunologic classification of acute lymphoblastic leukemia. Implications for normal lymphoid differentiation. Blood. 1980;56: 1120-1126.
3. Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia - current concepts and future perspectives. Rev Clin Exp Hematol. 2002;6.2:142-160; discussion 200-202.
4. Seiter K. Acute lymphoblastic leukemia. Available at: www.emedicine.com/med/topic3146.htm Last updated August 3, 2006.
5. Hoelzer D, Gokbuget N. Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol. 2000;36:49-58.
6. Satake N. Acute lymphoblastic leukemia. Available at: www.emedicine.com/ped/topic2587.htm Last updated: July 11, 2006.
7. Lionberger JM, Wilson MB, Smithgall TE. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem. 2000;275:18581-18585.
8. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357-2366.
9. Paul MK, Mukhopadhyay AK. Tyrosine kinase - role and significance in cancer. Int J Med Sci. 2004;1:101-115.
10. Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukemia. Acta Haematol. 2002;108:180-202.
11. Mughal TI, Goldman JM. Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation? Front Biosci. 2006;11:198-208.
12. Ottmann OG, Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2005:118-122.
13. Onciu M, Bueso-Ramos C, Medeiros J, Ball G, Smith T, Lai R. Acute lymphoblastic leukemia in elderly patients: The Philadelphia chromosome may not be a significant adverse prognostic factor. Am J Clin Pathol. 2002;117:716-720.
14. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001; 97:1572-1577.
15. Piccaluga PP, Martinelli G, Rondoni M, Visani G, Baccarani M. Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. Expert Opin Biol Ther. 2006;6:1011-1022.
16. Bloomfield CD, Secker-Walker LM, Goldman AI, et al. Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1989;40:171-185.
17. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia. 1991;5:196-199.
18. Gotz G, Weh HJ, Walter TA, et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol. 1992;64:97-100.
19. Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL1 fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B study. Blood. 1992;80:2983-2990.
20. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood. 1995;85:2025-2037.
21. Group Francais de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Groupe Francais de Cytogenetique Hematologique. Blood. 1996;87:3135-3142. Erratum in: Blood. 1996:88:2818.
22. Chim CS, Kwong YL, Chu YC, Chan CH, Chan YT, Liang R. Improved treatment outcome in adult acute lymphoblastic leukemia using the intensive German protocol, a preliminary report. Hematol Oncol. 1997;15:19-26.
23. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA.MRC Adult Leukaemia Working Party. Br J Haematol. 1997;96:601-610.
24. Thomas X, Thiebaut A, Olteanu N, et al. Philadelphia chromosome-positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther. 1998;40:119-128.
25. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999;93: 3983-3993.
26. Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000;36:263-273.
27. Ko BS, Tang JL, Tsai W, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in Taiwan. Ann Hematol. 2001;80:510-515.
28. Thomas X, Olteanu N, Charrin C, Lheritier V, Magaud JP, Fiere D. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol. 2001;67:73-83.
29. Thomas X, Danaila C, Le QH, et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21 year period. Leukemia. 2001;15:1811-1822.
30. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002; 99:863-871.
31. Manley PW, Cowan-Jacob E, Buchdunger E, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer. 2002; 38(suppl 5):S19-S27.
32. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042. Erratum in: N Engl J Med. 2001;345:232.
33. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemia. Blood. 2002;100:1965-1971.
34. Wassmann B, Pfeifer H, Scheuring UJ, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib. Blood. 2004;103: 1495-1498.
35. Piccaluga PP, Malagola M, Amabile M, et al. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. Haematologica. 2004;89:1269-1271.
36. Wassmann B, Pfeifer H, Scheuring U, et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Leukemia. 2002;16:2358-2365.
37. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103: 4396-4407.